- Home
- CPBI vs RFL Comparison
CPBI vs RFL Comparison
Compare CPBI & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | CPBI | RFL |
|---|---|---|
| Founded | 2023 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Real Estate |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.8M | 54.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CPBI | RFL |
|---|---|---|
| Price | $16.45 | $1.46 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.8K | ★ 143.0K |
| Earning Date | 01-01-0001 | 12-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.32 | N/A |
| EPS | ★ 0.96 | N/A |
| Revenue | ★ $19,961,000.00 | $1,029,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.14 | ★ N/A |
| Revenue Growth | 9.30 | ★ 47.63 |
| 52 Week Low | $13.00 | $1.17 |
| 52 Week High | $16.71 | $3.19 |
Technical Indicators
Market Signals| Indicator | CPBI | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 63.24 | 64.11 |
| Support Level | $16.26 | $1.21 |
| Resistance Level | $16.55 | $1.60 |
| Average True Range (ATR) | 0.09 | 0.08 |
| MACD | 0.04 | 0.04 |
| Stochastic Oscillator | 85.29 | 67.44 |
Price Performance
Historical ComparisonAbout CPBI Central Plains Bancshares Inc.
Central Plains Bancshares Inc operates as the bank holding company for Home Federal Savings and Loan Association of Grand Island that provides mortgage, consumer, commercial real estate, and commercial loans, The bank business consists mainly of accepting deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential mortgage loans secured by properties located in primary market area, as well as commercial real estate loans.
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.